Skip to main content
Fig. 1 | BMC Public Health

Fig. 1

From: Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa

Fig. 1

Decision tree showing possible approaches to evaluation of HBV infection in a simulated cohort of 10,000 antenatal women, and in their infants at age six months. P1 is the probability of women testing positive for HBsAg; P2 is the probability of women who are positive for HBsAg also testing positive for HBeAg; P3 is the probability of infants born to HBsAg+/HBeAg+ mothers testing HBsAg+ at 6 months of age; P4 is the probability of infants born to HBsAg+/HBeAg- mothers testing HBsAg+ at 6 months of age. HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; TDF: Tenofovir disoproxil fumarate

Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us